Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Male Breast Cancer Market

ID: MRFR/Pharma/17391-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026

US Male Breast Cancer Market Research Report By Type (Infiltrating Ductal Carcinoma, Inflammatory Breast Cancer, Paget Disease, Ductal Carcinoma), By Diagnosis (Mammography, Biopsy, Pet Scan, Others) and By Treatment (Local, Systemic) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Male Breast Cancer Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  49.     4.1.1 Ductal Carcinoma in Situ
  50.     4.1.2 Paget’s Disease of the Nipple
  51.     4.1.3 Inflammatory Breast Cancer
  52.     4.1.4 Infiltrating Ductal Carcinoma
  53.   4.2 Food, Beverages & Nutrition, BY Diagnosis (USD Million)
  54.     4.2.1 Mammography
  55.     4.2.2 Biopsy
  56.     4.2.3 Fine Needle Aspiration Biopsy
  57.     4.2.4 Core Biopsy
  58.     4.2.5 Excisional Biopsy
  59.     4.2.6 PET Scan
  60.     4.2.7 CT Scan
  61.     4.2.8 MRI Scan
  62.     4.2.9 Other Tests
  63.   4.3 Food, Beverages & Nutrition, BY Treatment (USD Million)
  64.     4.3.1 Local Treatments
  65.     4.3.2 Systemic Treatments
  66.   4.4 Food, Beverages & Nutrition, BY Local Treatments (USD Million)
  67.     4.4.1 Surgery
  68.     4.4.2 Radiation Therapy
  69.   4.5 Food, Beverages & Nutrition, BY Surgery (USD Million)
  70.     4.5.1 Mastectomy
  71.     4.5.2 Breast-Conserving Surgery
  72.     4.5.3 Lymph Nodes Biopsy
  73.   4.6 Food, Beverages & Nutrition, BY Systemic Treatments (USD Million)
  74.     4.6.1 Chemotherapy
  75.     4.6.2 Hormone Therapy
  76.     4.6.3 Targeted Therapy
  77.   4.7 Food, Beverages & Nutrition, BY Chemotherapy (USD Million)
  78.     4.7.1 Adjuvant Therapy
  79.     4.7.2 Neoadjuvant Therapy
  80.   4.8 Food, Beverages & Nutrition, BY Hormone Therapy (USD Million)
  81.     4.8.1 Using Drugs
  82.     4.8.2 Orchiectomy (Castration)
  83.   4.9 Food, Beverages & Nutrition, BY Targeted Therapy (USD Million)
  84.     4.9.1 For HER2 Positive Breast Cancer
  85.     4.9.2 For Hormone Receptor Positive Breast Cancer
  86.     4.9.3 For Cancer with BRCA Mutations
  87. 5 SECTION V: COMPETITIVE ANALYSIS
  88.   5.1 Competitive Landscape
  89.     5.1.1 Overview
  90.     5.1.2 Competitive Analysis
  91.     5.1.3 Market share Analysis
  92.     5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  93.     5.1.5 Competitive Benchmarking
  94.     5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  95.     5.1.7 Key developments and growth strategies
  96.       5.1.7.1 New Product Launch/Service Deployment
  97.       5.1.7.2 Merger & Acquisitions
  98.       5.1.7.3 Joint Ventures
  99.     5.1.8 Major Players Financial Matrix
  100.       5.1.8.1 Sales and Operating Income
  101.       5.1.8.2 Major Players R&D Expenditure. 2023
  102.   5.2 Company Profiles
  103.     5.2.1 Roche (CH)
  104.       5.2.1.1 Financial Overview
  105.       5.2.1.2 Products Offered
  106.       5.2.1.3 Key Developments
  107.       5.2.1.4 SWOT Analysis
  108.       5.2.1.5 Key Strategies
  109.     5.2.2 Novartis (CH)
  110.       5.2.2.1 Financial Overview
  111.       5.2.2.2 Products Offered
  112.       5.2.2.3 Key Developments
  113.       5.2.2.4 SWOT Analysis
  114.       5.2.2.5 Key Strategies
  115.     5.2.3 Pfizer (US)
  116.       5.2.3.1 Financial Overview
  117.       5.2.3.2 Products Offered
  118.       5.2.3.3 Key Developments
  119.       5.2.3.4 SWOT Analysis
  120.       5.2.3.5 Key Strategies
  121.     5.2.4 AstraZeneca (GB)
  122.       5.2.4.1 Financial Overview
  123.       5.2.4.2 Products Offered
  124.       5.2.4.3 Key Developments
  125.       5.2.4.4 SWOT Analysis
  126.       5.2.4.5 Key Strategies
  127.     5.2.5 Bristol-Myers Squibb (US)
  128.       5.2.5.1 Financial Overview
  129.       5.2.5.2 Products Offered
  130.       5.2.5.3 Key Developments
  131.       5.2.5.4 SWOT Analysis
  132.       5.2.5.5 Key Strategies
  133.     5.2.6 Merck & Co. (US)
  134.       5.2.6.1 Financial Overview
  135.       5.2.6.2 Products Offered
  136.       5.2.6.3 Key Developments
  137.       5.2.6.4 SWOT Analysis
  138.       5.2.6.5 Key Strategies
  139.     5.2.7 Eli Lilly and Company (US)
  140.       5.2.7.1 Financial Overview
  141.       5.2.7.2 Products Offered
  142.       5.2.7.3 Key Developments
  143.       5.2.7.4 SWOT Analysis
  144.       5.2.7.5 Key Strategies
  145.     5.2.8 Johnson & Johnson (US)
  146.       5.2.8.1 Financial Overview
  147.       5.2.8.2 Products Offered
  148.       5.2.8.3 Key Developments
  149.       5.2.8.4 SWOT Analysis
  150.       5.2.8.5 Key Strategies
  151.   5.3 Appendix
  152.     5.3.1 References
  153.     5.3.2 Related Reports
  154. 6 LIST OF FIGURES
  155.   6.1 MARKET SYNOPSIS
  156.   6.2 US MARKET ANALYSIS BY TYPE
  157.   6.3 US MARKET ANALYSIS BY DIAGNOSIS
  158.   6.4 US MARKET ANALYSIS BY TREATMENT
  159.   6.5 US MARKET ANALYSIS BY LOCAL TREATMENTS
  160.   6.6 US MARKET ANALYSIS BY SURGERY
  161.   6.7 US MARKET ANALYSIS BY SYSTEMIC TREATMENTS
  162.   6.8 US MARKET ANALYSIS BY CHEMOTHERAPY
  163.   6.9 US MARKET ANALYSIS BY HORMONE THERAPY
  164.   6.10 US MARKET ANALYSIS BY TARGETED THERAPY
  165.   6.11 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
  166.   6.12 RESEARCH PROCESS OF MRFR
  167.   6.13 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
  168.   6.14 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  169.   6.15 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  170.   6.16 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
  171.   6.17 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
  172.   6.18 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
  173.   6.19 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 (% SHARE)
  174.   6.20 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
  175.   6.21 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
  176.   6.22 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
  177.   6.23 FOOD, BEVERAGES & NUTRITION, BY LOCAL TREATMENTS, 2024 (% SHARE)
  178.   6.24 FOOD, BEVERAGES & NUTRITION, BY LOCAL TREATMENTS, 2024 TO 2035 (USD Million)
  179.   6.25 FOOD, BEVERAGES & NUTRITION, BY SURGERY, 2024 (% SHARE)
  180.   6.26 FOOD, BEVERAGES & NUTRITION, BY SURGERY, 2024 TO 2035 (USD Million)
  181.   6.27 FOOD, BEVERAGES & NUTRITION, BY SYSTEMIC TREATMENTS, 2024 (% SHARE)
  182.   6.28 FOOD, BEVERAGES & NUTRITION, BY SYSTEMIC TREATMENTS, 2024 TO 2035 (USD Million)
  183.   6.29 FOOD, BEVERAGES & NUTRITION, BY CHEMOTHERAPY, 2024 (% SHARE)
  184.   6.30 FOOD, BEVERAGES & NUTRITION, BY CHEMOTHERAPY, 2024 TO 2035 (USD Million)
  185.   6.31 FOOD, BEVERAGES & NUTRITION, BY HORMONE THERAPY, 2024 (% SHARE)
  186.   6.32 FOOD, BEVERAGES & NUTRITION, BY HORMONE THERAPY, 2024 TO 2035 (USD Million)
  187.   6.33 FOOD, BEVERAGES & NUTRITION, BY TARGETED THERAPY, 2024 (% SHARE)
  188.   6.34 FOOD, BEVERAGES & NUTRITION, BY TARGETED THERAPY, 2024 TO 2035 (USD Million)
  189.   6.35 BENCHMARKING OF MAJOR COMPETITORS
  190. 7 LIST OF TABLES
  191.   7.1 LIST OF ASSUMPTIONS
  192.     7.1.1
  193.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  194.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  195.     7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  196.     7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  197.     7.2.4 BY LOCAL TREATMENTS, 2025-2035 (USD Million)
  198.     7.2.5 BY SURGERY, 2025-2035 (USD Million)
  199.     7.2.6 BY SYSTEMIC TREATMENTS, 2025-2035 (USD Million)
  200.     7.2.7 BY CHEMOTHERAPY, 2025-2035 (USD Million)
  201.     7.2.8 BY HORMONE THERAPY, 2025-2035 (USD Million)
  202.     7.2.9 BY TARGETED THERAPY, 2025-2035 (USD Million)
  203.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  204.     7.3.1
  205.   7.4 ACQUISITION/PARTNERSHIP
  206.     7.4.1

US Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Type (USD Million, 2025-2035)

  • Ductal Carcinoma in Situ
  • Paget’s Disease of the Nipple
  • Inflammatory Breast Cancer
  • Infiltrating Ductal Carcinoma

Food, Beverages & Nutrition By Diagnosis (USD Million, 2025-2035)

  • Mammography
  • Biopsy
  • Fine Needle Aspiration Biopsy
  • Core Biopsy
  • Excisional Biopsy
  • PET Scan
  • CT Scan
  • MRI Scan
  • Other Tests

Food, Beverages & Nutrition By Treatment (USD Million, 2025-2035)

  • Local Treatments
  • Systemic Treatments

Food, Beverages & Nutrition By Local Treatments (USD Million, 2025-2035)

  • Surgery
  • Radiation Therapy

Food, Beverages & Nutrition By Surgery (USD Million, 2025-2035)

  • Mastectomy
  • Breast-Conserving Surgery
  • Lymph Nodes Biopsy

Food, Beverages & Nutrition By Systemic Treatments (USD Million, 2025-2035)

  • Chemotherapy
  • Hormone Therapy
  • Targeted Therapy

Food, Beverages & Nutrition By Chemotherapy (USD Million, 2025-2035)

  • Adjuvant Therapy
  • Neoadjuvant Therapy

Food, Beverages & Nutrition By Hormone Therapy (USD Million, 2025-2035)

  • Using Drugs
  • Orchiectomy (Castration)

Food, Beverages & Nutrition By Targeted Therapy (USD Million, 2025-2035)

  • For HER2 Positive Breast Cancer
  • For Hormone Receptor Positive Breast Cancer
  • For Cancer with BRCA Mutations

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓